BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23215684)

  • 1. Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells.
    Togami K; Tosaki Y; Chono S; Morimoto K; Hayasaka M; Tada H
    J Pharm Pharmacol; 2013 Jan; 65(1):22-9. PubMed ID: 23215684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
    Ming X; Knight BM; Thakker DR
    Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the clinical pharmacokinetics of fexofenadine enantiomers.
    Akamine Y; Miura M
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):429-434. PubMed ID: 29635947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y; Miura M; Komori H; Saito S; Kusuhara H; Tamai I; Ieiri I; Uno T; Yasui-Furukori N
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1087-95. PubMed ID: 24903351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
    Miura M; Uno T; Tateishi T; Suzuki T
    Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.
    Akamine Y; Miura M; Komori H; Tamai I; Ieiri I; Yasui-Furukori N; Uno T
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):352-7. PubMed ID: 26213156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.
    Ujie K; Oda M; Kobayashi M; Saitoh H
    Int J Pharm; 2008 Sep; 361(1-2):7-11. PubMed ID: 18572335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determinants of the stereoselective pharmacokinetics of fexofenadine].
    Akamine Y
    Yakugaku Zasshi; 2015; 135(3):473-81. PubMed ID: 25759055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional absorption of fexofenadine in rat intestine.
    MacLean C; Moenning U; Reichel A; Fricker G
    Eur J Pharm Sci; 2010 Dec; 41(5):670-4. PubMed ID: 20869437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
    Garver E; Hugger ED; Shearn SP; Rao A; Dawson PA; Davis CB; Han C
    Drug Metab Dispos; 2008 Dec; 36(12):2492-8. PubMed ID: 18755851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
    Tahara H; Kusuhara H; Maeda K; Koepsell H; Fuse E; Sugiyama Y
    Drug Metab Dispos; 2006 May; 34(5):743-7. PubMed ID: 16455804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
    Pinto L; Moreira FL; Nardotto GHB; Cavalli RC; Moisés ECD; Duarte G; Lanchote VL
    Pharm Res; 2020 Jun; 37(7):131. PubMed ID: 32557079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
    Dresser GK; Bailey DG; Leake BF; Schwarz UI; Dawson PA; Freeman DJ; Kim RB
    Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
    Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
    Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
    Pinto L; Bapat P; de Lima Moreira F; Lubetsky A; de Carvalho Cavalli R; Berger H; Lanchote VL; Koren G
    Pharm Res; 2021 Apr; 38(4):647-655. PubMed ID: 33825113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport characteristics of fexofenadine in the Caco-2 cell model.
    Petri N; Tannergren C; Rungstad D; Lennernäs H
    Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
    Qiang F; Lee BJ; Lee W; Han HK
    Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.
    Akamine Y; Miura M; Yasui-Furukori N; Ieiri I; Uno T
    J Clin Pharm Ther; 2015 Feb; 40(1):98-103. PubMed ID: 25263393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal drug transporter expression and the impact of grapefruit juice in humans.
    Glaeser H; Bailey DG; Dresser GK; Gregor JC; Schwarz UI; McGrath JS; Jolicoeur E; Lee W; Leake BF; Tirona RG; Kim RB
    Clin Pharmacol Ther; 2007 Mar; 81(3):362-70. PubMed ID: 17215845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
    Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
    Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.